A phase II study of erlotinib plus bevacizumab in patients with performance status 2 to 3 and EGFR mutation-positive advanced non-small-cell lung cancer
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000016507
- Lead Sponsor
- Shizuoka cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Not provided
Exclusion Criteria
1) EGFR mutation with T790M in exon 20 2) Uncontrolled symptomatic brain metastasis 3) Hemoptysis 4) Bleeding tendency 5) Use of antithrombotic agents 6) Evidence of tumor invading major blood vessel 7) Cavitated tumor 8) Thrombosis 9) Interstitial pneumonia or pulmonary fibrosis on imaging 10) Gastrointestinal disorder 11) Uncontrollable pleural effusion , ascites or pericardial effusion 12) Past given the radiation therapy for chest 13) Active double cancer 14) Severe complication 15) History of severe allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method